Cannvas Names Data Protection Officer and Plans for Expansion to Germany
Leveraging Many Networks to Access Global Markets
TORONTO, July 17, 2018 /CNW/ – Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC), a leading business technology company within the cannabis space, is pleased to announce the appointment of Radu Puscasu as Data Protection Officer. With over 14 years of experience, Radu has been heavily involved in creating meaningful customer relationship experiences through secure technology. He has held senior roles at Bell Media, TD Bank Securities (Equity Derivative Solutions and Data Management Services), and Pitney Bowes and has worked with client companies such as Takeda, AstraZenaca, Pfizer, and Novartis.
Cannvas is also pleased to announce its intention to expand into Germany, one of the fastest growing medical cannabis marketplaces in the world. The country has fully embraced medical cannabis as a legitimate, doctor-prescribed, insurance-paid, and pharmacy-provided medical and healthcare product.
“As part of our expansion into Germany and the European Union, I am very pleased to announce the appointment of Radu Puscasu to the role of Data Protection Officer,” said Steve Loutskou, Chief Operating Officer, Global Markets of Cannvas MedTech. “Data and information security has never been more important and we are taking the necessary step to ensure total and complete security with our patient-centric life sciences learning platform for the cannabis space. With Germany’s potential to become one of the largest consumer of medical cannabis in the world, we have been exploring our market entrance with a number of potential partners. We are leveraging our network built through the attendance of many trade events and conventions, and through our partners Tech West and PUF Ventures, to pursue beneficial partnerships on a global basis.”
With significant potential to improve the health and wellness of patients worldwide, the Cannvas.me platform will allow for global interaction of patients and consumers to medical practitioner and licensed producers. In January 2017, Germany fully embraced the medical benefits of cannabis and approved the substance as a legitimate, doctor-prescribed, pharmacy-provided, and perhaps most importantly insurance-paid, pharma product. As the most populous member of the 28 country European Union, Germany’s population of 82 million people accounts for 16% of the total population and 28% of the euro area economy, and represents a significant market opportunity for Cannvas.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
SOURCE Cannvas MedTech Inc.
For further information: www.cannvasmedtech.com; Media Inquiries: firstname.lastname@example.org; Investor Relations: email@example.com, 1-800-489-0116